Pacific Biosciences of California(US:PACB) ZACKSยท2025-09-12 23:16Group 1 - Pacific Biosciences of California (PACB) closed at $1.17, reflecting a -7.14% change from the previous day, underperforming the S&P 500's daily loss of 0.05% [1] - The stock has increased by 2.44% over the past month, which is below the Medical sector's gain of 7.77% and the S&P 500's gain of 3.44% [1] Group 2 - The company is expected to report an EPS of -$0.16, which is a 5.88% increase from the prior-year quarter, with a revenue estimate of $40.31 million, up 0.85% from the prior-year quarter [2] - For the annual period, the Zacks Consensus Estimates predict an EPS of -$0.6 and revenue of $159.08 million, indicating increases of +27.71% and +3.29% respectively from the last year [3] Group 3 - Recent changes in analyst estimates for Pacific Biosciences are important as they reflect short-term business trends, with positive revisions indicating analysts' confidence in the company's performance [4] - Adjustments in estimates are linked to stock price performance, and the Zacks Rank system is designed to leverage this relationship [5] Group 4 - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a strong track record, with 1 rated stocks averaging an annual return of +25% since 1988; currently, Pacific Biosciences holds a Zacks Rank of 3 (Hold) [6] Group 5 - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 94, placing it in the top 39% of over 250 industries, indicating strong performance potential [7]